

	<b>POLICY TITLE:</b> Final Report
<b>MANUAL NAME:</b> Clinical Operations	<b>POLICY NUMBER:</b> CR 1.3.1 <input type="checkbox"/> Addendum to Corporate Policy <input type="checkbox"/> Form Available In I-REPP System
<b>SECTION (as applicable):</b> Clinical Research	<b>POLICY OWNER:</b> Tedd Adair, Vice President of Clinical Operations and Chief Clinical Officer
<b>ORIGINATION DATE:</b> 01/01/2011	<b>FINAL APPROVAL DATE:</b> April 30, 2016

**POLICY:**

When submitting final trial reports, to ensure that the sponsor and the IRB/IEC receive adequate information on the conduct of the trial after it is completed.

**SCOPE:**

This procedure applies to all clinical trials conducted at any IASIS facility.

**DEFINITIONS:**

Not Applicable

**PROCEDURE:**

***Reports:***

Upon completion of the investigator's participation in a trial, final reports are submitted as follows:

- A summary of the trial's outcome is submitted to the IRB/IEC in the format requested by the IRB/IEC.
- Any final reports requested by the sponsor are complete and submitted to the sponsor according to their specifications.

Once a study is complete and the final report has been submitted to the IRB, the investigator must continue to honor any commitments regarding the confidentiality of identifiable patient health information/study data or any other commitments that are consistent with the IRB-approved investigational plan (e.g. notification of study results to participants).

***Responsibility:***

- The Principal Investigator/assigned party, with assistance from applicable site operations staff, is responsible for ensuring the submission of the final report to the IRB/IEC.
- The study coordinator is responsible for ensuring that all required reports are submitted to the sponsor.
- The Principal Investigator and other members of the research team are responsible for continuing to honor any commitments regarding the confidentiality of identifiable patient health information/study data or any other commitments

**FORM REFERENCES:**

Not Applicable

**REFERENCES:**

Food and Drug Administration CFR Title 21 Part 56

<b>Review/Revised Date:</b>	<b>Title:</b>	<b>Description of Change or Location of Change in Document:</b>
04/30/2016	Tedd Adair VP Clinical Operations & CCO	Scheduled review; converted to ISO Policy Template